When symptoms become side effects: Development of the side effect attribution scale (SEAS).


Journal

Journal of psychosomatic research
ISSN: 1879-1360
Titre abrégé: J Psychosom Res
Pays: England
ID NLM: 0376333

Informations de publication

Date de publication:
02 2021
Historique:
received: 26 05 2020
revised: 07 12 2020
accepted: 09 12 2020
pubmed: 23 12 2020
medline: 13 4 2021
entrez: 22 12 2020
Statut: ppublish

Résumé

Symptom misattribution is a central process in the nocebo effect but it is not accurately assessed in current side effect measures. We have developed a new measure, the Side Effect Attribution Scale (SEAS), which examines the degree to which people believe their symptoms are treatment side effects. The SEAS was tested in three New Zealand studies: a vaccination sample (n = 225), patients with gout or rheumatoid arthritis (n = 102), and patients switching to a generic medicine (n = 69). The internal reliability of the scale was examined using Cronbach's alpha. To assess validity, the Side Effect Attribution Total Score and Side Effect Attribution Binary Score were related to a number of psychological measures associated with side effect reporting. The scale showed good internal reliability across the three studies, with Cronbach alphas ranging from 0.840 to 0.943. Analysis of the effect sizes showed that the Attribution Total Score was generally more strongly associated with nocebo responding than Attribution Binary Score. Participants had greater Side Effect Attribution Total Scores if they had higher expectations for vaccination side effects (r = 0.18, p = .028), more worry about future vaccine effects (r = 0.16, p = .046), a higher perceived sensitivity to medicines (r = 0.50, p < .001), greater anxiety (r = 0.25, p = .016), greater intentional non-adherence (r = 0.30, p = .003), greater medicine information seeking (r = 0.26, p = .010), lower trust in pharmaceutical agencies (r = -0.29, p = .026), and lower medicine efficacy beliefs (r = -0.46, p < .001). The SEAS provides a more nuanced assessment of symptom attribution beliefs. It appears to be more sensitive measure than just a side effect total, as it is associated with a greater number of relevant psychological variables. Future research should examine the scale in other populations and settings.

Identifiants

pubmed: 33352479
pii: S0022-3999(20)30902-8
doi: 10.1016/j.jpsychores.2020.110340
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

110340

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Kate MacKrill (K)

Department of Psychological Medicine, University of Auckland, Auckland, New Zealand.

Rebecca Webster (R)

Department of Psychology, University of Sheffield, Sheffield, United Kingdom.

G James Rubin (GJ)

Department of Psychological Medicine, King's College London, London, United Kingdom.

Michael Witthöft (M)

Department of Clinical Psychology, Psychotherapy and Experimental Psychopathology, Johannes Gutenberg University of Mainz, Germany.

Connor Silvester (C)

Department of Psychological Medicine, University of Auckland, Auckland, New Zealand.

Yasaman Emad (Y)

Department of Psychological Medicine, University of Auckland, Auckland, New Zealand.

Keith J Petrie (KJ)

Department of Psychological Medicine, University of Auckland, Auckland, New Zealand. Electronic address: kj.petrie@auckland.ac.nz.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH